Fulgent Genetics Inc (FLGT)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 36.12% | 32.20% | 32.03% | 39.24% | 59.28% | 67.68% | 73.69% | 77.01% | 78.29% | 80.19% | 79.34% | 79.33% | 78.70% | 69.16% | 55.90% | 56.47% | 56.63% | 55.58% | 52.30% | 50.64% |
| Operating profit margin | -67.61% | -28.27% | -26.29% | -13.22% | 28.84% | 45.58% | 56.73% | 64.08% | 68.10% | 72.50% | 72.03% | 72.28% | 68.80% | 47.25% | 4.17% | -1.49% | -1.32% | -3.52% | -13.56% | -21.29% |
| Pretax margin | -57.62% | -21.25% | -21.46% | -10.25% | 29.98% | 46.11% | 57.09% | 64.75% | 68.73% | 72.94% | 72.18% | 71.89% | 68.02% | 45.61% | 4.55% | -1.13% | -1.13% | -4.02% | -14.49% | -23.21% |
| Net profit margin | -58.03% | -22.17% | -15.84% | -7.10% | 23.17% | 33.82% | 42.41% | 48.32% | 51.12% | 54.96% | 54.24% | 53.91% | 50.82% | 35.31% | 5.78% | -1.31% | -1.26% | -7.27% | -16.84% | -25.40% |
Fulgent Genetics Inc's profitability ratios have shown significant fluctuations over the past eight quarters. The gross profit margin, a measure of a company's ability to generate profit from its core activities, has declined from 59.28% in Q4 2022 to 36.12% in Q4 2023, indicating potential challenges in controlling production costs or pricing strategies.
The operating profit margin, which reflects the efficiency of the company in managing its operating expenses, has also witnessed a sharp decline, shifting from 29.32% in Q4 2022 to -26.03% in Q4 2023. This suggests that the company may be facing cost overruns or operational inefficiencies impacting its profitability.
Furthermore, both the pretax and net profit margins have also exhibited negative trends, with significant decreases from Q4 2022 to Q4 2023. The pretax margin dropped from 29.73% to -60.19%, while the net profit margin decreased from 23.17% to -58.03%. These declines indicate that Fulgent Genetics Inc's bottom-line profitability has been severely impacted, possibly by increased expenses or a decrease in revenue.
In conclusion, based on these profitability ratios, Fulgent Genetics Inc appears to be facing challenges in maintaining its profitability and financial performance. The company may need to focus on cost-cutting measures, operational improvements, or strategic pricing decisions to enhance its profitability in the future.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -15.83% | -5.96% | -5.97% | -3.50% | 12.88% | 26.03% | 35.91% | 41.69% | 52.86% | 62.34% | 62.41% | 55.95% | 41.42% | 25.81% | 1.90% | -0.58% | -0.48% | -1.71% | -6.03% | -8.44% |
| Return on assets (ROA) | -13.59% | -4.68% | -3.59% | -1.88% | 10.35% | 19.32% | 26.84% | 31.43% | 39.68% | 47.26% | 47.00% | 41.73% | 30.60% | 19.29% | 2.64% | -0.51% | -0.46% | -3.55% | -7.49% | -10.07% |
| Return on total capital | -15.67% | -4.80% | -5.19% | -2.92% | 14.64% | 29.01% | 40.49% | 47.27% | 58.88% | 72.47% | 71.49% | 69.37% | 50.38% | 32.93% | 2.19% | -0.64% | -0.52% | -1.92% | -6.65% | -9.41% |
| Return on equity (ROE) | -14.77% | -5.05% | -3.86% | -2.05% | 11.32% | 21.27% | 30.07% | 35.27% | 43.79% | 54.91% | 54.06% | 52.02% | 37.64% | 25.52% | 2.91% | -0.56% | -0.50% | -3.98% | -8.26% | -11.22% |
Fulgent Genetics Inc's profitability ratios show a decline in performance from Q1 2022 to Q4 2023. The Operating Return on Assets (Operating ROA) notably deteriorated from 41.69% in Q1 2022 to -6.10% in Q4 2023, indicating a significant decrease in the company's operating efficiency in generating profits from its assets.
Similarly, the Return on Assets (ROA) and Return on Total Capital also experienced a downward trend, reflecting a decline in the company's overall profitability and capital efficiency over the period. The ROA decreased from 31.43% in Q1 2022 to -13.59% in Q4 2023, while the Return on Total Capital decreased from 46.03% to -6.62% during the same period.
Furthermore, the Return on Equity (ROE) also exhibited a negative trend, dropping from 35.27% in Q1 2022 to -14.77% in Q4 2023. This indicates a reduction in the company's ability to generate returns for its shareholders from the equity invested in the business.
Overall, the profitability ratios of Fulgent Genetics Inc suggest a concerning decline in financial performance and efficiency in utilizing assets and capital to generate profits and returns for shareholders. Further analysis and investigation into the underlying factors driving these deteriorating profitability metrics would be necessary to assess the company's financial health and prospects for improvement.